Roivant Sciences (ROIV) Gains from Investment Securities (2020 - 2025)

Roivant Sciences has reported Gains from Investment Securities for 6 years, with the latest figure at $2.5 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities rose 225.32% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at $3.3 million (down 90.01% YoY), and the FY2026 full-year result was $2.5 million, down 98.19% from the prior year.
• Gains from Investment Securities for Q4 2025 stood at $2.5 million, down from $11.1 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $444.6 million in Q3 2021, with the low at -$11.1 million in Q2 2025.
• Historically, Gains from Investment Securities has averaged $69.6 million across 5 years, with a median of $21.5 million in 2023.
• The largest YoY upside for Gains from Investment Securities was 225.32% in 2025 against a maximum downside of 3468.39% in 2025.
• Roivant Sciences' Gains from Investment Securities stood at $1.2 million in 2021, then soared by 6334.85% to $74.7 million in 2022, then tumbled by 57.37% to $31.8 million in 2023, then sank by 97.57% to $774000.0 in 2024, then soared by 225.32% to $2.5 million in 2025.
• The last three Gains from Investment Securities figures came in at $2.5 million (Q4 2025), $11.1 million (Q3 2025), and -$11.1 million (Q2 2025), per Business Quant data.